Malignant glioblastomas represent the most common type of primary brain tumor in adults and are considered incurable (Schoenberg, 1983; Hochberg and Pruitt 1987) . Therapeutic approaches to malignant gliomas include surgery, radiation and chemotherapy, but are of limited eectiveness and novel treatment modalities must be explored. Epidemiological, clinical and laboratory data suggest that glioblastomas and other brain tumors are hormone-sensitive (Olson et al., 1988; Pinski et al., 1993; Poisson et al., 1983; Paoletti et al., 1990; Schally and Comaru-Schally, 1997) . It has also been shown that astrocytomas and meningiomas express signi®cant levels of high-anity receptors for bombesin or structurally-related gastrinreleasing peptide (GRP) (Moody et al., 1989; Staley et al., 1993) . In a recent study performed by Sharif et al. (1997) , the high majority (85%) of human glioblastoma cell lines expressed functional receptors for bombesin/ GRP.
Bombesin-like peptides were initially reported as autocrine growth factors in small cell lung carcinoma (SCLC) (Moody et al., 1981) , but later were shown to be implicated in growth of other cancers (Schally and Comaru-Schally, 1997) . Peptides of bombesin/GRP family induce cell proliferation by mechanisms that involve stimulation of phosphatidylinositol, Ca 2+ release, and induction of c-fos and c-jun oncogenes (Moody et al., 1987; Spindel et al., 1993; Draoui et al., 1995) . Antagonists of bombesin/GRP can inhibit the growth of SCLC in vivo and in vitro (Mahmoud et al., 1991; Pinski et al., 1994a; Koppan et al., 1998; Halmos and Schally, 1997 ]bombesin(6 ± 14) developed in our laboratory suppressed the growth of other tumors including gastric, pancreatic, colorectal, breast, prostatic cancers, and brain tumors in vivo (Pinski et al., 1994b, c, d; Szepeshazi et al., 1991 Szepeshazi et al., , 1992 , supporting the view that bombesin-like peptides are involved in the pathogenesis of a wide range of human tumors. ] bombesin(6 ± 14) (Reile et al., 1995) on the growth of U-87MG glioblastomas xenografted in nude mice. These peptide analogs dier at N-terminus and in position 14 (C-terminal). RC-3095 contains N-terminal D-Tpi and C-terminal Leu, and RC-3940-II has Hca at N-terminus and Tac (thiazolidine-4-carboxylic acid) at C-terminus. Due to this structural dierence, RC-3940-II has a more restricted conformation than RC-3095 which results in about 200 times higher binding anity to GRP receptor than RC-3095 (Reile et al., 1995) ]Bombesin in Swiss 3T3 cells. Thus, it was interesting to include both analogs in our study in order to investigate whether the dierences in the binding properties of these bombesin/GRP antagonists were re¯ected in their antiproliferative action in vivo.
We have previously shown that U-87MG glioblastomas express high-anity binding sites for bombesin/ GRP (K d , 6.1+0.5 nM) (Pinski et al., 1994d) . The eects of GRP, RC-3095, and RC-3940-II on the expression of mRNA for c-fos oncogene in U-87MG tumors were also investigated.
Athymic nude mice bearing s.c. xenografts of U-87MG human glioblastomas were initiated as described (Pinski et al., 1994d) . When tumors reached a volume of approximately 70 mm 3 , mice were randomized and divided into three experimental groups of seven mice each which received s.c. the following treatment for 4 weeks: group 1, 0.08 M acetic acid in saline; group 2, bombesin/GRP antagonist RC-3095 (D-22213) at a dose of 20mg/animal/day; and group 3, bombesin/GRP antagonist RC-3940-II (D-24197) at a dose of 20 mg/animal/day. RC-3095 and RC-3940-II were dissolved in 0.08 M acetic acid in saline. Tumor volume and body weight were recorded weekly as described (Pinski et al., 1994d) . At the end of the experiment, 3 h after the last injection, the mice were sacri®ced by decapitation using methoxy¯urane anesthesia and tumors were cleaned, weighed and samples were stored in 7708C for mRNA analysis. Our results are summarized in Table 1 (Figure 1 ). The mean tumor weight was also reduced signi®cantly (P50.01) by RC-3095 and RC-3940-II compared with the control group (Table 1) . At the end of the experiment no signi®cant dierences were detected in body weights and the weight of various organs such as lung, heart, liver, and kidneys between the groups (data not shown), indicating that treatment with RC-3095 and RC-3940-II was not toxic to the tumor-bearing animals.
RT ± PCR analyses demonstrated that U-87MG tumors express mRNA for bombesin receptor subtype (BRS)-1 (GRP receptor) and BRS-2 (neuromedin B receptor), but not mRNA for BRS-3 ( Figure 2a ). The nucleotide sequence and the expected PCR products for the oligonucleotide primers used are shown in Table 2 . In order to determine whether U-87MG cells also express mRNA for GRP, total RNA isolated from U-87MG xenografts and U-87MG cells cultured in vitro was reverse-transcribed and subjected to PCR ampli®cation using primers that span the common region of the prepro-GRP to the 3'-untranslated region of the message (Siegfried et al., 1994) . No band of the expected size was found after electrophoresis of the PCR products in a 2% agarose gel, suggesting that U-87MG glioblastomas do not produce the GRP ligand ( Figure 2b ). Although the detection of the mRNA for GRP by more sensitive methods such as nested PCR and/or Southern blot hybridization cannot be excluded, the autocrine stimulation of this tumor by GRP might be much less physiologically important than paracrine stimulation.
In order to con®rm the negative results for GRP expression obtained by the RT ± PCR and considering that physiologically active GRP should be secreted by the cells, a radioimmunoassay (RIA) was performed for the detection of GRP as described (Moody and Pert, 1979) , using antibody Ab aBN 2 , a gift from Dr T Moody (NCI. Rockville, MD, USA). In conditioned media from U-87MG cells cultured in vitro, corresponding to 48 h and 96 h of culture, no immunoreactive GRP was detected suggesting that these cells do not produce a physiologically active GRP.
In an attempt to investigate further the mechanism of antitumor action of bombesin/GRP antagonists, the role of GRP(14 ± 27) in the expression of mRNA for cfos oncogene was investigated. In vivo, treatment of mice bearing U-87MG xenografts with RC-3095 or RC-3940-II resulted in a decrease in the mRNA levels for c-fos oncogene in the range of 30% (P50.01) and 40% (P50.01) respectively, versus the corresponding levels of the controls (Figure 3) . The levels of c-jun oncogene were also investigated in tumors from mice treated with RC-3095 and RC-3940-II, but no signi®cant eect was found as compared with the controls (data not shown). We then cultured U-87MG cells for 18 h in vitro as described previously (Pinski et al., 1994d) , except that the tissue culture medium contained 2.5% v/v heat-inactivated, dextran-coated, charcoal-treated fetal bovine serum (Yano et al., 1992) . Subsequently, cells were exposed to 10 77 M GRP(14 ± 27) for 1 h. The mRNA levels of c-fos oncogene were assessed by RT ± PCR at various time periods after the exposure to GRP(14 ± 27). As shown in Figure 3 , the maximal stimulation of c-fos mRNA levels, about 230% vs basal, was obtained 2 h after the exposure to GRP(14 ± 27), while after 8 h c-fos mRNA returned to basal levels. The induction of c-fos by GRP(14 ± 27) in U-87MG glioblastomas extends the observations of Draoui et al. (1995) who found that bombesin stimulates the expression of c-fos mRNA in SCLC cell lines.
The stimulation of c-fos mRNA by GRP(14 ± 27) could be suppressed by the bombesin/GRP antagonist RC-3940-II, when the latter was added to the culture medium at equimolar concentration and incubated with GRP(14 ± 27) (see Figure 4 for details). In this experiment, RC-3940-II did not signi®cantly aect the mRNA levels for c-fos when added to the culture medium alone, indicating the absence of any intrinsic Table 2 . All RNA preparations were previously normalized with respect to the expression of hGAPDH Table 2 Nucleotide sequence and size of the expected PCR products for oligonucleotide primers used for RT-PCR a in the present study 
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a Total RNA was isolated using the RNAzolB reagent (TEL-TEST, Inc., Friendswood, TX, USA) following the manufacturer's instructions. RT ± PCR was performed using a kit from Perkin-Elmer (Norwalk, CT, USA) according to the instructions of the manufacturer, using a Stratagene Robocycler (La Jolla, CA, USA). Subsequently, aliquots of the PCR products were electrophoresed in a 2% agarose gel, stained with ethidium bromide and quanti®ed densitometrically using a scanning densitometer (BioRad, CA, USA). All experiments were repeated at least twice and similar results were obtained activity in this peptide analog (Figure 4) . We then tested whether GRP(14 ± 27) also stimulates the mRNA for c-jun. A moderate induction of c-jun oncogene, about 150% vs basal, was also found 2 h after the stimulation of U-87MG cells with GRP(14 ± 27), while 4 ± 8 h later c-jun mRNA levels returned to basal levels ( Figure 5b ). In order to investigate whether these ®ndings concerning the eects of GRP on the mRNA levels of c-fos and c-jun oncogenes in U-87MG cells represent a more general mechanism of the action of GRP on glioblastomas, U-373MG human glioblastomas were subjected to similar analysis. U-373MG cells express high anity binding sites for bombesin/GRP (K d , Figure 3 Expression of c-fos mRNA in U-87MG and U-373MG glioblastomas. Total RNA was extracted from cells or tumors, and c-fos and hGAPDH mRNAs were co-ampli®ed by multiplex RT ± PCR and electrophoresed on 2% agarose. Exposure to the peptide analogs was followed by 2 h-culture of the cells in control medium, in order to obtain the optimum stimulation of c-fos (see Figure 3c,d) . M, DNA molecular size marker Figure 5 Expression of c-jun mRNA in U-87MG and U-373MG glioblastomas. Total RNA was extracted from cells, and c-jun and hGAPDH cDNAs were co-ampli®ed by multiplex RT ± PCR and electrophoresed on 2% agarose. (Pinski et al., 1994d) which are due to the expression of BRS-1 (GRP receptor) as demonstrated by RT ± PCR (Figure 2c ). GRP mRNA was not detected in U-373MG cells (Figure 2d ) and immunoreactive GRP was not found by RIA in conditioned media from these cells. Exposure of U-373MG cells to GRP(14 ± 27) at 10 77 M for 1 h resulted in a timedependent induction of the mRNA for c-fos, the maximal eect, about 300% vs basal, occurring 2 h after the stimulation and returning to basal levels after 4 ± 8 h (Figure 3d ). The levels of mRNA for c-jun also increased about 200% vs basal, 2 h after the stimulation with GRP(14 ± 27) and returned to basal levels 8 h later. As in the case of U-87MG cells, RC-3940-II could block the induction of c-fos caused by GRP, in U-373MG cells (Figure 4) . The stimulation of the mRNA for c-fos and c-jun oncogenes by GRP(14 ± 27), is in agreement with our previous ®ndings concerning the eects of GRP analogs on the proliferation of U-87MG and U-373MG cells in vitro. Pinski et al. (1994d) showed that RC-3095 at 10 77 M concentration inhibited the growth of U-87MG and U-373MG cells in vitro, by approximately 40 and 60% respectively, in the presence of 10 75 M GRP(14 ± 27). Similar experiments on cancer cell lines that respond to bombesin-like peptides, indicated that exposure to low concentrations of GRP(14 ± 27) results in stimulation of growth, while exposure of the same cells to higher concentrations of GRP(14 ± 27) may produce growth inhibition (Qin et al., 1994a; Wang et al., 1996; Kiaris and Schally, unpublished data) .
The precise molecular mechanism by which GRP stimulates the expression of the mRNA for c-fos oncogene in U-87MG and U-373MG human glioblastomas is incompletely understood. Previous studies showed that bombesin/GRP-like peptides stimulate phosphatidylinositol and Ca 2+ release (Moody et al., 1987; Spindel et al., 1993) , while antagonistic analogs of bombesin/GRP downregulate the receptor for epidermal growth factor (Halmos and and inhibit the phosphorylation responses induced by bombesin-like peptides (Liebow et al., 1994) . It is possible that the cascade of intracellular events initiated by the binding of bombesin/GRP-like peptides to speci®c membrane receptors could result in the induction of c-fos oncogene. The products of c-fos and c-jun oncogenes are proteins that form a complex which regulates the expression of genes with AP-1 activation elements (Halazonetis et al., 1988; O'Shea et al., 1989) . Among the genes with such AP-1 regulatory elements is the gene encoding for the GRP ligand (Draoui et al., 1993; , suggesting a positive regulation of GRP mRNA by its product, the GRP ligand, through a mechanism that involves the c-fos oncogene. Thus, c-fos might be involved in the mechanism of action of bombesin-like peptides including GRP, not only in SCLC in which these peptides can function as autocrine growth factors, but also in other tumors such as U-87MG and U-373MG malignant glioblastomas in which GRP induces the expression of c-fos oncogene and stimulates tumor growth by a paracrine mechanism.
Although an autocrine role for neuromedin B (NMB) in the stimulation of U-87MG and U-373MG human glioblastomas cannot be excluded, the lower anity of NMB for BRS-1 (Spindel et al., 1993) suggests that the results obtained by the speci®c bombesin/GRP antagonists in our study were due to the blockade of BRS-1. If NMB, produced in an autocrine manner, stimulated mRNA for c-fos by acting upon BRS-1, the exposure of U-87MG and U-373MG cells in vitro to RC-3940-II, should have resulted in a decrease of c-fos mRNA levels ( Figure  4a ,b, lane 4). In addition, the interaction between NMB and BRS-2, should remain unaected by the speci®c BN/GRP antagonists used in our study.
Our study suggests that the paracrine production of GRP could be implicated in the pathogenesis of U-87MG glioblastomas. Antagonistic analogs of bombesin/GRP suppress the growth of U-87MG cells in vivo by a mechanism that probably involves the suppression of c-fos proto-oncogene. Our work supports the merit of further studies with bombesin/GRP antagonists aimed at development of methods for the treatment of malignant glioblastomas.
